#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating patients with non-alcoholic fatty liver disease now have preliminary evidence that CBD and CBG may offer therapeutic benefits beyond current standard care, particularly for metabolic complications like hyperglycemia and dyslipidemia. These findings could inform future clinical trials and inform discussions with patients seeking adjunctive treatments for NAFLD, though evidence remains limited and regulatory pathways for cannabis-derived therapeutics remain unclear. Understanding cannabinoid mechanisms in hepatic metabolism may help clinicians better counsel patients on cannabis use and support development of evidence-based guidelines for this growing therapeutic area.
This preclinical study demonstrates that cannabidiol (CBD) and cannabigerol (CBG) may offer therapeutic potential for non-alcoholic fatty liver disease by improving glycemic control and reducing circulating lipids associated with hepatic steatosis. While the mechanisms appear promising, these findings are preliminary and derived from laboratory research rather than human clinical trials, limiting direct applicability to current clinical practice. The results suggest a potential therapeutic avenue for a common metabolic condition affecting millions of patients, particularly those with obesity and diabetes who have few pharmacologic options beyond lifestyle modification. Clinicians should be cautious about recommending cannabis products for fatty liver disease until well-designed randomized controlled trials in human subjects establish safety, efficacy, and appropriate dosing. For now, patients asking about cannabis for metabolic liver disease should be counseled that evidence remains preliminary and that established interventions such as weight loss and management of underlying metabolic disorders remain the standard of care.
“What we’re seeing in the lab with CBD and CBG is metabolic improvement at the cellular level, but I’m careful with patients not to oversell this as a treatment until we have clinical trial data in humans showing sustained benefit and safety over time, because fatty liver disease is progressive and my job is to prevent harm while we wait for the evidence to mature.”
💊 While preclinical evidence suggesting cannabidiol and cannabigerol may improve metabolic parameters relevant to nonalcoholic fatty liver disease is intriguing, clinicians should recognize that in vitro and animal models often fail to translate to human efficacy and safety, and no robust clinical trials have yet established these compounds as therapeutic agents for this condition. The study’s findings regarding blood glucose and lipid improvements are encouraging but remain preliminary, and important confounders—including optimal dosing, long-term hepatic effects, drug interactions, and impact on the underlying pathophysiology of NAFLD—remain poorly characterized in humans. Additionally, the variable cannabinoid content and lack of standardization in commercial cannabis products complicate any potential clinical application. Until well-designed randomized controlled trials in human populations are completed and regulatory pathways clarified, clinicians should not recommend cannabis-derived cannabinoids for fatty liver disease outside of research settings, though the
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: